tbuckley/cabot-search huggingface dataset:
Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders
Authors: Dinah S. Reddihough, Catherine Marraffa, Anissa Mouti, Molly O’Sullivan, Katherine J. Lee, Francesca Orsini, Philip Hazell, Joanna Granich, Andrew J. O. Whitehouse, John Wray, David Dossetor, Paramala Santosh, Natalie Silove, Michael Kohn
Journal: JAMA (2019)

Selective serotonin receptor inhibitors are prescribed to reduce the severity of core behaviors of autism spectrum disorders, but their efficacy remains uncertain.To determine the efficacy of fluoxetine for reducing the frequency and severity of obsessive-compulsive behaviors in autism spectrum disorders.Multicenter, randomized, placebo-controlled clinical trial. Participants aged 7.5-18 years with autism spectrum disorders and a total score of 6 or higher on the Children's Yale-Brown Obsessive Compulsive Scale, modified for pervasive developmental disorder (CYBOCS-PDD) were recruited from 3 tertiary health centers across Australia. Enrollment began November 2010 and ended April 2017. Follow-up ended August 2017.Participants were randomized to receive fluoxetine (n = 75) or placebo (n = 71). Study medication was commenced at 4 or 8 mg/d for the first week, depending on weight, and then titrated to a maximum dose of 20 or 30 mg/d over 4 weeks. Treatment duration was 16 weeks.The primary outcome was the total score on the CYBOCS-PDD (scores range from 0-20; higher scores indicate higher levels of maladaptive behaviors; minimal clinically important difference, 2 points) at 16 weeks postrandomization, analyzed with a linear regression model adjusted for stratification factors (site, age at baseline, and intellectual disability), with an additional prespecified model that included additional adjustment for baseline score, sex, communication level, and imbalanced baseline and demographic variables.Among the 146 participants who were randomized (85% males; mean age, 11.2 years), 109 completed the trial; 31 in the fluoxetine group and 21 in the placebo group dropped out or did not complete treatment. The mean CYBOCS-PDD score from baseline to 16 weeks decreased in the fluoxetine group from 12.80 to 9.02 points (3.72-point decrease; 95% CI, -4.85 to -2.60) and in the placebo group from 13.13 to 10.89 points (2.53-point decrease; 95% CI, -3.86 to -1.19). The between-group mean difference at 16 weeks was -2.01 (95% CI, -3.77 to -0.25; P = .03) (adjusted for stratification factors), and in the prespecified model with further adjustment, it was -1.17 (95% CI, -3.01 to 0.67; P = .21).In this preliminary study of children and adolescents with autism spectrum disorders, treatment with fluoxetine compared with placebo resulted in significantly lower scores for obsessive-compulsive behaviors at 16 weeks. Interpretation is limited by the high dropout rate, null findings of prespecified analyses that accounted for potentially confounding factors and baseline imbalances, and CIs for the treatment effect that included the minimal clinically important difference.anzctr.org.au Identifier: ACTRN12608000173392.
P2.05-17 Preoperative Identification of the Left Common Pulmonary Vein for Safe Video-Assisted Lobectomy
Authors: S. Kikuchi, Y. Sekine, K. Sugai, T. Kawamura, T. Yanagihara, Y. Saeki, S. Kitazawa, N. Kobayashi, Y. Goto, M. Onizuka, H. Ichimura, Y. Sato
Journal: Journal of Thoracic Oncology (2019)
P2.04-28 NeoCOAST: Neoadjuvant Durvalumab Alone or with Novel Agents for Resectable, Early-Stage (I–IIIA) Non-Small Cell Lung Cancer
Authors: R. Garcia Campelo, P. Forde, W. Weder, J. Spicer, P. He, O. Hamid, P. Martinez, T. Cascone
Journal: Journal of Thoracic Oncology (2019)
TCT-199 Improvement Of Left Ventricular Function Assessment By Global Longitudinal Strain After Successful Percutaneous Coronary Intervention For Chronic Total Occlusions
Authors: Misato Chimura, Shinichiro Yamada, Yoshinori Yasaka, Tetsuari Onishi, Seiichi Kobayashi, Takahiro Sawada, Shogo Oishi, Takayoshi Toba, Taishi Miyata, Hiroya Kawai
Journal: Journal of the American College of Cardiology (2014)
OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC
Authors: M. Garassino, D. Rodriguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, G. Speranza, M. Reck, R. Hui, M. Boyer, R. Cristescu, D. Aurora-Garg, A. Albright, A. Loboda, J. Kobie, J. Lunceford, M. Ayers, G. Lubiniecki, B. Piperdi, M.C. Pietanza, E. Garon
Journal: Journal of Thoracic Oncology (2019)
Seasonal mortality in terminally ill cancer patients
Authors: J. Policzer, B. Kinzbrunner, D. Tanis
Journal: Journal of Clinical Oncology (2009)

6575 Background: There is ample evidence that the death rate in elderly patients increases in winter months. The increase in deaths may be amplified in terminally ill patients where place of care home, hospital, or long-term care facility might play a significant role in seasonal mortality. In this paper, we compare seasonal variation in death rates for terminally ill cancer patients to terminally ill patients who are “frail,” i.e., those with neurodegenerative disease, general debility, or chronic heart failure. Methods: We reviewed monthly deaths for Medicare patients age 65 or older with terminal cancer or “frail” patients who were admitted to one of 45 hospice programs and died on service between January 2004 and November 2008. The 72,066 records were analyzed using a three-way analysis of variance (season, place of care, diagnosis) with Bonferroni correction for post-hoc comparisons. Results: Compared to frail patients who died during June, July, and August, the number of deaths of frail patients increased an average of 20% in January, February, and March. This near-sinusoidal pattern was remarkably consistent over a five year period. The effect was most pronounced in patients in nursing facilities, followed by those in hospital, and then by patients receiving home care (all p &lt; 0.005). For cancer patients, this seasonal variation was not observed in any place of care (all p &gt; 0.05). Conclusions: Although frail patients generally have a longer length of stay in hospice than cancer patients hence allowing more opportunity for exposure to infection a number of other factors may serve to insulate cancer patients from seasonal effects. These include a smaller “symptom burden” than frail patients, who frequently have comorbid disease(s) and who are often unable to make their needs known; less compromised immune systems; more aggressive medical treatment; better nutrition; a strong support system (particularly from family and caregivers); and increased sensitivity to factors that may prolong survival, e.g., timely immunizations and even the avoidance of crowds in winter months. No significant financial relationships to disclose.
Having a named doctor in general practice is not enough to improve continuity of care
Authors: Denis Pereira Gray, Kate Sidaway-Lee, Philip Evans, Alex Harding
Journal: BMJ (2019)

Mahase reports on research by Tammes and colleagues showing that having named doctors in general practice is not effective.12 This is not surprising, as without further interventions it remains an administrative process only.

Simply allocating the name of a GP to patients, as general practices are required to do by contract, does nothing to …
Living Trees: High-Quality Reproducible and Reusable Construction of Bacterial Phylogenetic Trees
Authors: Dalong Hu, Bin Liu, Lei Wang, Peter R Reeves
Journal: Molecular Biology and Evolution (2019)

Abstract An ideal bacterial phylogenetic tree accurately retraces evolutionary history and accurately incorporates mutational, recombination and other events on the appropriate branches. Current strain-level bacterial phylogenetic analysis based on large numbers of genomes lacks reliability and resolution, and is hard to be replicated, confirmed and reused, because of the highly divergent nature of microbial genomes. We present SNPs and Recombination Events Tree (SaRTree), a pipeline using six “living trees” modules that addresses problems arising from the high numbers and variable quality of bacterial genome sequences. It provides for reuse of the tree and offers a major step toward global standardization of phylogenetic analysis by generating deposit files including all steps involved in phylogenetic inference. The tree itself is a “living tree” that can be extended by addition of more sequences, or the deposit can be used to vary the programs or parameters used, to assess the effect of such changes. This approach will allow phylogeny papers to meet the traditional responsibility of providing data and analysis that can be repeated and critically evaluated by others. We used the Acinetobacter baumannii global clone I to illustrate use of SaRTree to optimize tree resolution. An Escherichia coli tree was built from 351 sequences selected from 11,162 genome sequences, with the others added back onto well-defined branches, to show how this facility can greatly improve the outcomes from genome sequencing. SaRTree is designed for prokaryote strain-level analysis but could be adapted for other usage.
P1.01-102 Actionable Gene Aberration and the Response of Matched Therapy Among Patients with Non-Small-Cell Lung Carcinoma
Authors: T. Mizuno, Y. Fujiwara, N. Yamamoto, K. Sunami, T. Kubo, T. Ichikawa, R. Morita, J. Sato, Y. Goto, H. Horinouchi, S. Kanda, S. Murakami, T. Yoshida, Y. Ohe, T. Kohno
Journal: Journal of Thoracic Oncology (2019)

Tumor genotyping using multiplex gene panel is now standard for precision medicine in non-small-cell lung carcinoma (NSCLC). We sought to assess the prevalence of actionable genomic alterations among NSCLC patients using our next-generation sequencing panel (NCC Oncopanel) and the response of matched therapy. This is a post-hoc analysis of prospective study in which patients with advanced solid cancer were prospectively enrolled to undergo the comprehensive genomic profiling panel (NCC Oncopanel) conducted between July 2013 and March 2018 in National Cancer Center Hospital. The NCC Oncopanel assay, a multiplexed next-generation sequencing (NGS) assay of 114 cancer-associated genes, was performed in a CLIA-compliant laboratory in National Cancer Center. Subjects were primarily patients without any known actionable alteration such as EGFR or ALK. Patients with NSCLC were extracted into this analysis. Clinical data and treatment outcomes were retrospectively collected. In total, 100 patients were extracted. Sufficient tumor tissue for NGS analysis were available in 91 patients; median age was 57 (range 30‒77); 74 (81.3%) adenocarcinoma; 44 (48.4%) female; 42 (46.2%) never smoker. According to the OncoKB and CIViC database, and the Clinical Practice Guidelines for NGS in Cancer Diagnosis and Treatment issued by three major Japanese cancer-related societies, 85 patients (93.4%) had at least one potential pathogenic alteration. Actionable gene aberrations were identified in 49 (53.9%). Evidence levels were ranked as follows: 24 (26%) harbored level 1 aberrations (ALK, EGFR, ROS1, BRAF); 15 (16%) harbored level 2 (RET, DDR2, MET, ATM, BRCA2, CDK4, CTNNB1, EZH2, JAK2, NRAS, TSC1); 10 (11%) harbored level 3A (CDKN2A, ERBB2, HRAS, PTEN, SMARCA4, STK11). Matched therapy was administered into 29 (31.9%) leading to the objective response rate of 58.6% and the disease control rate of 79.3% with the median progression-free survival of 10.5 months (95%CI; 5.1‒15.8). Multiplex gene panel is feasible and useful in screening candidates for matched therapy among NSCLC patients. NSCLC patients without any known actionable mutations should be considered to undergo comprehensive genomic profiling.
P1.18-12 PACIFIC-4/RTOG 3515: Phase III Study of Durvalumab Following SBRT for Unresected Stage I/II, Lymph-Node Negative NSCLC
Authors: C. Robinson, C. Hu, M. Machtay, M. Newton, K. Wu, K. Barrett, P. Dennis, J. Bradley
Journal: Journal of Thoracic Oncology (2019)
P2.05-15 Radial Endobronchial Ultrasound-Guided Transbronchial Biopsy in Peripheral Lung Lesions. What Can Cryobiopsy Contribute?
Authors: S. Baeza Mena, M. Torky, C. Centeno Clemente, R. Tazi Mezalek, I. García Olivé, J..L. Mate Sanz, R. López Martos, P. Lopez De Castro, T. Moran, E. Carcereny, A. Rosell, F. Andreo García
Journal: Journal of Thoracic Oncology (2019)
Current Prevalence of Specific Clinical Outcomes in Adult Patients with Hb SS or Hb Sβ0 Thalassemia.
Authors: Laura M. De Castro, Felicia C. Lennon-Graham, Allison G. Ashley-Koch, Jude C. Jonassaint, James J. Eckman, Eugene P. Orringer, Marilyn J. Telen
Journal: Blood (2006)
Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study
Authors: N. Daneman, D. Chateau, M. Dahl, J. Zhang, A. Fisher, I.S. Sketris, J. Quail, F. Marra, P. Ernst, S. Bugden
Journal: Clinical Microbiology and Infection (2019)

ObjectivesThe United States Food & Drug Administration released an advisory in 2016 that fluoroquinolones be relegated to second-line agents for uncomplicated urinary tract infections (UTIs) given reports of rare but serious side effects; similar warnings have followed from Health Canada and the European Medicines Agency. The objective was to determine whether alternative non-fluoroquinolone agents are as effective as fluoroquinolones in the treatment of UTIs.MethodsWe conducted a retrospective population-based cohort study using administrative health data from six Canadian provinces. We identified women (n = 1 585 997) receiving antibiotic treatment for episodes of uncomplicated UTIs (n = 2 857 243) between January 1 2005 and December 31 2015. Clinical outcomes within 30 days from the initial antibiotic dispensation were compared among patients treated with a fluoroquinolone versus non-fluoroquinolone agents. High-dimensional propensity score adjustments were used to ensure comparable treatment groups and to minimize residual confounding.ResultsFluoroquinolone use for UTI declined over the study period in five of six Canadian provinces and accounted for 22.3–48.5% of treatments overall. The pooled effect across the provinces indicated that fluoroquinolones were associated with fewer return outpatient visits (OR 0.89, 95%CI 0.87–0.92), emergency department visits (OR 0.74, 95%CI 0.61–0.89), hospitalizations (OR 0.83, 95%CI 0.77–0.88), and repeat antibiotic dispensations (OR 0.77, 95%CI 0.75–0.80) within 30 days.ConclusionsFluoroquinolones are associated with improved clinical outcomes among women with uncomplicated UTIs. This benefit must be weighed against the risk of fluoroquinolone resistance and rare but serious fluoroquinolone side effects when selecting first-line treatment for these patients.
P2.17-14 Impaired Immune Defense in Tumor Micro-Environment Is Associated with Risk of Recurrence in Early Stage Lung Adenocarcinoma
Authors: Y. Lou, A. Khoor, M. Thomas, J. Kachergus, Y. Ma, Y. Zhang, R. Chen, K. Knutson, A. Thompson
Journal: Journal of Thoracic Oncology (2019)
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Authors: Kendra Sweet, Rami Komrokji, Eric Padron, Christopher L. Cubitt, Joel G. Turner, Junmin Zhou, Alan F. List, David A. Sallman, Jana L. Dawson, Daniel M. Sullivan, Julio Chavez, Bijal D. Shah, Jeffrey E. Lancet
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Induction chemotherapy results in complete remission (CR) rates of 20% to 50% among patients with poor-risk AML. Selinexor is an oral selective inhibitor of nuclear export with promising single-agent activity. By inhibiting the primary export protein, XPO1, selinexor localizes and activates tumor suppressor proteins in the nucleus and inhibits DNA damage repair, rationalizing combination with DNA-damaging agents. Patients and Methods: This was a single-arm phase I clinical trial of selinexor combined with cytarabine and daunorubicin (7+3). Dose escalation was selinexor alone (3+3) with an expansion at the MTD. Cohorts 1 and 2 received 60 and 80 mg orally, respectively, twice weekly during induction. Consolidation cycles (≤ 2) with selinexor at induction dose plus 5+2 were allowed for patients who achieved CR. MTD and recommended phase II dose of selinexor were the primary endpoints. Results: Twenty-one patients with poor-risk AML were enrolled. All 21 patients were included in the safety evaluations and survival analyses (4 in each of 2 cohorts; 13 in the expansion); 8 (53%) of the 19 patients evaluable for response achieved CR/CRi. MTD was not reached. Selinexor 80 mg (orally, twice weekly) was used in the expansion phase. The most common grade 3/4 nonhematologic treatment-emergent adverse events were febrile neutropenia (67%), diarrhea (29%), hyponatremia (29%), and sepsis (14%). At median follow-up (28.9 months), 38% of patients were alive. Median overall survival was 10.3 months. Conclusions: Selinexor plus 7+3 is a safe regimen for patients with newly diagnosed poor-risk AML and warrants further investigation in a larger clinical trial.
MA16.07 Implementation of a Smartphone App to Face Postoperative Period in Patients with NSCLC Undergoing Lung Resection Surgery
Authors: C. Fraile Olivero, L. Milla Collado, J. Jarabo Sarceda, E. Fernández Martín, C. Cerdan Santacruz, J. Gastardi, A. Gómez Martínez, P. Arribas Manzanal, P. Santos Capa, M. Martínez Tardido, V. Alen, F. Hernando-Trancho
Journal: Journal of Thoracic Oncology (2019)
P1.01-93 Metastases Sites as a Prognostic Factor in a Real-World Multicenter Cohort Study of Spanish ALK-Positive NSCLC Patients (p)
Authors: L. Angelats, R. Garcia Campelo, R. Bernabe, E. Arriola, P. Rocha, V. Calvo De Juan, E. Sais, A. Barba, N. Viñolas, M. Gil Moreno, L. Vilà, O. Juan, N. Vilariño, M. Cobo, M. Domine, S. Vazquez, J. Coves, R. Marse-Fabregat, A.M. Esteve Gomez, E. Carcereny
Journal: Journal of Thoracic Oncology (2019)
MA08.03 Adjuvant Pembrolizumab in N2 Positive NSCLC Treated with Concurrent Chemoradiotherapy Followed by Surgery: Phase II, Prospective Study
Authors: S. Park, H.A. Jung, J.H. Cho, J. Sun, H.K. Kim, S. Lee, Y.S. Choi, J.S. Ahn, J. Kim, K. Park, J.I. Zo, Y.M. Shim, M. Ahn
Journal: Journal of Thoracic Oncology (2019)
EP1.01-69 Safety and Efficacy of Percutaneous Computed Tomography-Guided Thermal Ablation of Non-Small Cell Lung Cancer Metastases
Authors: K. Tavernaraki, I. Gkiozos, D. Grapsa, A. Charpidou, P. Nikolopoulos, E. Kokkotou, I. Kotteas, L. Thanos, K. Syrigos
Journal: Journal of Thoracic Oncology (2019)
P1.01-77 Impact of Oral Drugs on the Prognosis of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
Authors: Y. Taniguchi, A. Tamiya, S. Isa, K. Nakahama, K. Okishio, T. Shiroyama, H. Suzuki, T. Inoue, M. Tamiya, T. Hirashima, F. Imamura, S. Atagi
Journal: Journal of Thoracic Oncology (2019)
A Modified Post-Transplant Cyclophosphamide (PT-CY) Regimen, Following Unmanipulated Haploidentical Bone Marrow Transplantation, for Acute Myeloid Leukemia: A Multicenter Study
Authors: Patrizia Chiusolo, Gesine Bug, Attilio Olivieri, Brune Mats, Nicola Mordini, Emilio Paolo Alessandrino, Alida Dominietto, Anna Maria Raiola, Carmen Di Grazia, Francesca Gualandi, Maria Teresa van Lint, Emanuele Angelucci, Andrea Bacigalupo
Journal: Blood (2016)
P2.09-02 Exploring the Features of the Short and Long-Term Survivors for Lung Adenocarcinoma: A Single Center Experience
Authors: L. Ventura, L. Gnetti, C. Braggio, G. Bocchialini, M. Tiseo, E.M. Silini, P. Carbognani, M. Rusca, L. Ampollini
Journal: Journal of Thoracic Oncology (2019)
P1.09-04 Comprehensive Genomic Profiling in a Brazilian Cohort of Lung Cancer Patients: Real-World Impact
Authors: T. Padua, M. Monteiro, M. Silvino, L. Carvalho, T. Sousa, C. Bognar, E. Brabo, M. Campelo, D. Limeira, A.B. Abrahao, M. Zukin, R. Moreira, L.H. Araújo
Journal: Journal of Thoracic Oncology (2019)
FEV<sub>1</sub>:FVC Thresholds for Defining Chronic Obstructive Pulmonary Disease
Authors: Carlos A. Vaz Fragoso
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P1.13-07 Comparison of the 7th and 8th Edition of TNM Staging for NSCLC in Patients Undergoing Pulmonary Resection After Neoadjuvant/Induction Treatment
Authors: H. Melek, T. Sevinç, G. Çetinkaya, A. Bayram, A. Deligönül, E. Çubukçu, T. Evrensel, S. Sarıhan, C. Gebitekin
Journal: Journal of Thoracic Oncology (2019)
EP1.12-29 Retrospective Study About Small Cell Lung Cancer: Our Experience in a Spanish Hospital
Authors: D. Sanchez Cabrero, P. Cruz, S. Martinez, P. Perez, O. Higuera, A. Pertejo, I. Esteban, L. Gutierrez, J. Villamayor, D. Viñal, J.L. Torres, J. Ramón, J. De Castro Carpeno
Journal: Journal of Thoracic Oncology (2019)
P1.01-34 Early Assessment of Therapy Response in Non-Small Cell Lung Cancer (NSCLC) via Longitudinal ctDNA Analysis
Authors: S. Yaung, X. Ma, C. Ju, C. Woestmann, L. Xi, B. Hinzmann, M. Thomas, C. Heussel, F. Lasitschka, M. Meister, M. Schneider, F. Herth, T. Muley, B. Wehnl, J. Palma
Journal: Journal of Thoracic Oncology (2019)
The New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
Authors: Yuliya Lytvyn, Petter Bjornstad, Daniel H van Raalte, Hiddo L Heerspink, David Z I Cherney
Journal: Endocrine Reviews (2019)

Abstract Diabetic kidney disease remains the most common cause of end-stage kidney disease in the world. Despite reductions in incidence rates of myocardial infarction and stroke in people with diabetes over the past 3 decades, the risk of diabetic kidney disease has remained unchanged, and may even be increasing in younger individuals afflicted with this disease. Accordingly, changes in public health policy have to be implemented to address the root causes of diabetic kidney disease, including the rise of obesity and diabetes, in addition to the use of safe and effective pharmacological agents to prevent cardiorenal complications in people with diabetes. The aim of this article is to review the mechanisms of pathogenesis and therapies that are either in clinical practice or that are emerging in clinical development programs for potential use to treat diabetic kidney disease.